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Steroid 5-alpha-reductase 2 deficiency is a rare disorder leading to male pseudohermaphroditism, a condition characterized by
incomplete differentiation of male genitalia in 46,XY patients. Here, we report a case of a 21-year-old woman from Ardabil who
presented with primary amenorrhea, ambiguous genitalia, and lack of breast development. All of the serum hormone profiles were
normal except for raised serum total testosterone. Testosterone to DHT ratio (T/DHT) was elevated before (15.72) and further
increased after hCG stimulation (32.46). A chromosomal study revealed a 46,XY karyotype. A bilateral gonadectomy, recessive
cliteroplasty, urethroplasty, and vaginoplasty were performed and hormonal replacement therapy using estrogen was started. In
conclusion, the diagnosis of 5-alpha-reductase 2 deficiency may be suspected in infants with ambiguous genitalia or in adolescents
or young adults with the characteristic phenotype and serum hormone profiles.
1. Introduction
Steroid 5-alpha-reductase 2 deficiency, a 46,XY disorder of
sexual development (DSD) [1], is an autosomal recessive
condition in which 46,XY subjects with bilateral testes and
normal testosterone formation have impaired virilization
during embryogenesis due to defective conversion of testos-
terone to dihydrotestosterone [2, 3]. Dihydrotestosterone
(DHT) is essential for the normal development of male
external genitalia. DHT is derived from testosterone (T)
by a process catalysed by the membrane-bound steroid 5a-
reductase enzyme [4].The enzyme steroid 5𝛼-reductase exists
in two isoforms, 5𝛼-R type 1 and 5𝛼-R type 2, which have
different expression patterns. Type 1 isoenzyme is encoded by
the SRD5A1 gene located on chromosome 5 and expressed
at low levels in the prostate, whereas type 2 isoenzyme is
encoded by the SRD5A2 gene that maps on chromosome 2
and is expressed at high levels in the prostate and in many
other androgen sensitive tissues [5]. 5𝛼-reductase deficiency
is caused by mutations in the SRD5A2 gene, whereas the
SRD5A1 gene has not been found to be mutated in this dis-
ease. Althoughmost individualswith 5𝛼-reductase deficiency
are identified in the neonatal period because of ambiguous
genitalia, some are misdiagnosed with androgen insensitivity
syndrome, as they often present with the same clinical
phenotype, while others escape recognition completely.
In this report, we demonstrate a case of steroid 5-
alpha-reductase 2 deficiency that presented with primary
amenorrhea and lack of breast development.
2. Case Presentation
A 21-year-old unmarried woman presented to our medical
outpatient department with complaint of primary amenor-
rhea and lack of breast development. There was no history
of significant medical illness in the past. She was born out of
a nonconsanguineous marriage. Menstrual history revealed
that she never attained menarche. There is no history of
2 Case Reports in Endocrinology
Figure 1: Clitoromegaly and ambiguous genitalia.
Figure 2: Lack of breast development.
significant medical illness in the family. She also had a deep
voice. On examination, blood pressure was 110/70mmHg
without significant asymmetry or postural variation with
palpable pulses in all extremities. She weighed 71 kg and her
height was 174 cm with a body mass index of 23.5 kg/m2.
General physical examination was within normal limits (no
features suggestive of hypothyroidism, Cushing’s syndrome,
or acromegaly). Her Tanner staging was B2P4A2. External
genitalia examination revealed clitoromegaly (4 cm) and
ambiguous genitalia (Figures 1 and 2). Gonads were palpable
in the inguinal canal bilaterally. She underwent a gynaecolog-
ical examination which showed a 5 cm blind vaginal pouch.
Ultrasonogram of abdomen and pelvis showed atrophic
uterus and bilateral ill-defined gonad-like structures high up
in pelvic.
Blood investigations showed normal hemogram. Her
blood glucose, renal function tests, liver function tests,
and serum electrolytes were within normal limits. In view
of primary amenorrhea with clitoromegaly, serum total
testosterone, LH, FSH, 17-OH Progesterone, DHEAS, thyroid
profile, and prolactin were measured. All of the above
hormone investigations were normal except for raised serum
total testosterone. A chromosomal study revealed a 46,XY
karyotype. The diagnosis of 5𝛼-reductase deficiency was
suspected based on biochemical findings at base line and
following hCG stimulation test (hCG 3000 units daily for 3
consecutive days). As shown in Table 1, the patient’s testos-
terone to DHT ratio (T/DHT) was elevated before (15.72)
and further increased after hCG stimulation (32.46). The
Table 1: Results of the hCG stimulation test.
Hormones Before hCGstimulation test
After hCG
stimulation test
Total testosterone (nmol/L) 19.5 39.6
DHT (nmol/L) 1.24 1.22
T/DHT 15.72 32.46
Androstenedione (nmol/L) 6.8 6.5
DHEAS (nmol/L) 4535.2 5435.5
diagnosis of 17𝛽-HSD-3, whichmay have similar clinical pre-
sentation, seemed unlikely because of the normal response of
androstenedione.
A bilateral gonadectomy, recessive cliteroplasty, urethro-
plasty, and vaginoplasty were performed and hormonal
replacement therapy using estrogen was started.
3. Discussion
Steroid 5𝛼-reductase 2 deficiency is an autosomal recessive
form of male pseudohermaphroditism caused by mutations
in the SRD5A2 gene. Over 50 different mutations have been
described [5]. The typical clinical features in 46,XY males
with 5-alpha-reductase 2 deficiency are those reported in
the two originally recognized families as follows [2, 3].
(1) The external genitalia usually are predominately female
at birth, with the exception of clitoromegaly in some, so
that most affected males are raised as females. A variable
degree of virilization occurs at the time of puberty. (2) The
internal urogenital tract is male, consisting of epididymis,
vasa deferentia, seminal vesicles, and ejaculatory ducts that
empty into a blind-ending vagina. The absence of mu¨llerian
duct derivatives indicates that anti-mu¨llerian hormone is
produced and acts normally. (3) Pubertal gynecomastia may
occur, but does not persist into adulthood.
A wide spectrum of phenotypes was reported in a subse-
quent study of 55 patients with 5-alpha-reductase 2 deficiency
including the following [6]: clitoromegaly was present in 27
(49 percent), microphallus in 18 (33 percent), and normal
female external genitalia in only four (7.3 percent). 40 patients
(72 percent) were initially assigned to female gender, and of
these, five (12.5 percent) switched to male sex at puberty.
Concentrations of serum testosterone and estrogens
are similar to those in normal men. The level of serum
luteinizing hormone (LH) is normal in about one-half of
subjects and slightly elevated in the rest. Levels of serum
follicle-stimulating hormone (FSH) are elevated. Because
of the defect in 5-alpha-reductase 2, the ratio of serum
testosterone to dihydrotestosterone is increased, basically
in adults and after administration of human chorionic
gonadotropin (hCG) in childhood. In the initial descriptions,
affected subjects were identified because phenotypic females
failed to menstruate and developed variable virilization at
adolescence. Now that many affected families have been
reported, it is apparent that the manifestations vary [7].
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Approximately 55 percent of affected subjects have a blind-
ending or pseudovagina in which the Wolffian ducts termi-
nate in the upper vagina. 40 percent of the Wolffian ducts
terminate in the perineum on either side of the urethra. The
remainder is sufficiently virilized to be assigned male gender
at birth.The testes are invariably outside the abdominal cavity
either in the inguinal canals, labia majora, or scrotum, and
spermatogenesis is impaired.
One report of four individuals diagnosed as adults with
intact testes found normal lumbar and hip bone mineral
density in three individuals and mild lumbar osteopenia in
the fourth [8]. In another study of 16 adult subjects with
the disorder, hip bone mineral density was not significantly
different than a reference male population [9].
Gender role behavior can change from the female sex
of rearing to male at the time of expected puberty. In a
large extended kindred from the Dominican Republic, as
an example, 18 of 19 subjects initially raised as females
subsequently changed gender-role behavior to male at the
time of puberty [10]. In other reports, approximately 50 to 60
percent of affected individuals assigned female sex in infancy
and virilizing in puberty changed their gender role behavior
to male [11]. The percentage of patients changing gender
role was much lower (12.5 percent) in the report described
above [6], perhaps due to different societal responses to the
condition in the different communities studied. Homozy-
gous 46,XX women with 5-alpha-reductase 2 deficiency are
phenotypically normal and have normal menstruation and
normal fertility, but menarche may be delayed [12, 13].
The diagnosis of 5-alpha-reductase 2 deficiency may be
suspected in infants with ambiguous genitalia or in adoles-
cents or young adults with the characteristic phenotype and
serum hormone profiles (normal male serum testosterone
concentration and increased ratio of serum testosterone to
dihydrotestosterone). Measurement of basal concentrations
of serum testosterone and dihydrotestosterone is usually
sufficient for diagnosis after the expected age of puberty.
The ratio of serum testosterone to dihydrotestosterone was
>20 in affected subjects in the extended kindred from the
Dominican Republic [14] and in another nine unrelated
Brazilian families [15]. In the latter study, the ratio ranged
from 35 to 84 in affected subjects as compared to 8 to 16
in normal subjects. In adults, measurement of the ratio of
serum testosterone to dihydrotestosterone after administra-
tion of hCG or testosterone does not increase discrimination
between affected and normal men. Definitive diagnosis of
the mutation in the steroid 5-alpha-reductase 2 enzyme can
be made by cDNA analysis using peripheral blood, biopsy
material, or fibroblast cultures [16].
Gonadectomy should be performed to prevent or min-
imize virilization and to prevent development of tumors in
inguinal or labial testes [17]. Clitoromegaly may be surgically
corrected by an appropriate procedure to maintain the glans
clitoris. If vaginal development is insufficient, vaginal depth
should be enhanced by use of dilators at the appropriate age,
and, if this is unsuccessful, an artificial vagina should be
created surgically [18]. Estrogen therapy that is appropriate
for inducing and maintaining feminization should be started
at the time of usual pubertal maturation or immediately after
gonadectomy is performed in an adult. Such therapy is critical
to promote breast development and to prevent osteoporosis.
Since virilization is usually less than satisfactory, even when
some phallic growth occurs after the time of sexual matura-
tion, trials of supplemental androgen are sometimes under-
taken [15, 19]. Although pharmacologic doses of testosterone
esters may raise serum dihydrotestosterone concentrations
to the normal range and cause acne and growth of facial
and body hair, phallic growth is minimal in adults, and the
long-term safety of this treatment is not established. The
results are different in prepubertal subjects. In one report,
as an example, pharmacologic doses of testosterone (two
intramuscular doses of testosterone ester 125mg three weeks
apart) led to more than a doubling of penis size [15]. An
alternate approach is to administer dihydrotestosterone itself,
either in the formof a transdermal cream [20] or an injectable
ester [21]. Both modes of dihydrotestosterone administration
raise serum dihydrotestosterone concentrations [20, 21], but
neither preparation is commercially available, and an optimal
regimen has not been established.
Based on the findings of the present case, it is highly
recommended that patients presenting with primary amen-
orrhea, ambiguous genitalia, and lack of breast development
perform serum hormone profiles (LH, FSH, 17-OH Proges-
terone, DHEAS, and hCG stimulation test and measurement
of testosterone to DHT ratio) to reveal this rare disorder.
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